Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

XLV vs. LOGSX: which is better?

Bottom line

XLV vs LOGSX: the short answer

XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and LOGSX (Live Oak Health Sciences Fund) are quite different portfolios: only about 31% of their top holdings (by weight) are shared.

But XLV is far broader, holding 65 positions to 28 for LOGSX, so beyond the top names it adds exposure LOGSX doesn't have.

XLV is cheaper at 0.08% vs 1.04% — a difference of $96 a year per $10,000 invested.

Over five years, LOGSX returned +8.1% a year vs +8.1% for XLV.

Updated Nov 19, 2026

XLV vs LOGSX side by side

XLVLOGSX
TypeETFMutual fund
Fund familySPDR (State Street)Oak Associates
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.08%1.04%
Annual cost per $10k$8$104
10-yr cost on $10k (prospectus)$103$1,271
Max front loadNone—
12b-1 fee0.02%—
1-yr return+14.5%+19.6%
5-yr return (annualized)+8.1%+8.1%
10-yr return (annualized)+9.8%+7.3%
Best quarter+14.5%+13.4%
Worst quarter−12.7%−13.1%
Net assets (fund)$40.6B$56.1M
Number of holdings6528
Portfolio turnover2%24%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearXLVLOGSXDifference
2025+14.5%+19.6%−5.1%
2024+2.5%+0.2%+2.3%
2023+2.0%+1.2%+0.8%
2022−2.1%+3.7%−5.8%
2021+25.9%+17.5%+8.4%
2020+13.3%+6.0%+7.3%
2019+20.7%+19.0%+1.7%
2018+6.3%−4.0%+10.2%
2017+21.7%+13.4%+8.3%
2016−2.8%−0.4%−2.5%

Source: Fund prospectus bar charts

Holdings overlap

13 of XLV's top 25 holdings also appear in LOGSX's top 25.

Shared top holdings
HoldingXLVLOGSX
Eli Lilly & Co16.51%1.99%
Johnson & Johnson10.64%3.77%
Merck & Co Inc5.52%3.16%
Amgen Inc3.40%4.86%
Gilead Sciences Inc2.73%3.50%
Intuitive Surgical Inc2.45%2.99%
Vertex Pharmaceuticals Inc2.19%3.26%
Bristol-Myers Squibb Co2.05%4.02%
McKesson Corp1.58%4.53%
Cigna Group/The1.27%3.46%
Regeneron Pharmaceuticals Inc1.08%4.43%
Cardinal Health Inc0.97%5.86%
Cencora Inc0.96%4.46%

Source: SEC Form N-PORT

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

LOGSX top 10

  1. N/a — 6.91%
  2. Cardinal Health Inc — 5.86%
  3. Jazz Pharmaceuticals Plc — 5.77%
  4. United Therapeutics Corp — 5.11%
  5. Exelixis Inc — 4.95%
  6. Amgen Inc — 4.86%
  7. Lantheus Holdings Inc — 4.68%
  8. Novartis Ag — 4.67%
  9. Mckesson Corp — 4.53%
  10. Cencora Inc — 4.46%

FAQ

What is the difference between XLV and LOGSX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and LOGSX (Live Oak Health Sciences Fund) are quite different portfolios: only about 31% of their top holdings (by weight) are shared. But XLV is far broader, holding 65 positions to 28 for LOGSX, so beyond the top names it adds exposure LOGSX doesn't have.
Which is cheaper, XLV or LOGSX?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and LOGSX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.